Gene transfer of matrix metalloproteinase-9 induces tumor regression of breast cancer in vivo

Cancer Research

Volumn 68, Issue 9, 2008, Pages 3405-3412

  Bendrik, Christina ^a   Robertson, Jennifer ^b   Gauldie, Jack ^b   Dabrosin, Charlotta ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GELATINASE B; MATRIX METALLOPROTEINASE INHIBITOR; TAMOXIFEN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VASCULOTROPIN; ENDOSTATIN; VASCULOTROPIN A;

ARTICLE; BREAST CANCER; DRUG MECHANISM; ENZYME ACTIVITY; GENETIC TRANSFECTION; IN VIVO STUDY; PRIORITY JOURNAL; TUMOR REGRESSION; ADENOCARCINOMA; ADENOVIRUS; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CELL CULTURE; DISEASE COURSE; DRUG SCREENING; FEMALE; GENE THERAPY; GENE TRANSFER; GENETICS; HUMAN; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; REMISSION; TUMOR VOLUME;

ADENOCARCINOMA; ADENOVIRIDAE; ANIMALS; BREAST NEOPLASMS; DISEASE PROGRESSION; ENDOSTATINS; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; REMISSION INDUCTION; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR BURDEN; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 44849137555     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-0295     Document Type: Article

References (39)

1. Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms of metastasis. Cancer 1997;80:1529-37.
2. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827-39.
3. Chang C, Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 2001;11:S37-43.
4. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000;2:252-7.
5. Liotta LA, Stetler-Stevenson WG. Metalloproteinases and cancer invasion. Semin Cancer Biol 1990;1:99-106.
6. Stetler-Stevenson WG, Yu AE. Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol 2001;11:143-52.
7. Cornelius LA, Nehring LC, Harding E, et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 1998;161:6845-52.
8. Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaisse J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 2000;486:247-51.
9. Hamano Y, Zeisberg M, Sugimoto H, et al. Physiological levels of tumstatin, a fragment of collagen IV α3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via αV β3 integrin. Cancer Cell 2003;3:589-601.
10. Nilsson UW, Dabrosin C. Estradiol and tamoxifen regulate endostatin generation via matrix metalloproteinase activity in breast cancer in vivo. Cancer Res 2006;66:4789-94.
11. Lopez-Otin C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007;7:800-8.
12. Martin MD, Matrisian LM. The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev 2007;26:717-24.
13. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-92.
14. Overall CM, Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006;6:227-39.
15. Dabrosin C. Variability of vascular endothelial growth factor in normal human breast tissue in vivo during the menstrual cycle. J Clin Endocrinol Metab 2003;88:2695-8.
16. Dabrosin C. Positive correlation between estradiol and vascular endothelial growth factor but not fibroblast growth factor-2 in normal human breast tissue in vivo. Clin Cancer Res 2005;11:8036-41.
17. Dabrosin C, Margetts PJ, Gauldie J. Estradiol increases extracellular levels of vascular endothelial growth factor in vivo in murine mammary cancer. Int J Cancer 2003;107:535-40.
18. Garvin S, Dabrosin C. Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo. Cancer Res 2003;63:8742-8.
19. Nilsson UW, Garvin S, Dabrosin C. MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cells. Breast Cancer Res Treat 2007;102:253-61.
20. Partridge JJ, Madsen MA, Ardi VC, et al. Functional analysis of MMPs and TIMPs differentially expressed by variants of human HT-1080 fibrosarcoma exhibiting high and low levels of intravasation and metastasis. J Biol Chem 2007;282:35964-77.
21. Ng P, Parks RJ, Cummings DT, et al. A high-efficiency Cre/loxP-based system for construction of adenoviral vectors. Hum Gene Ther 1999;10:2667-72.
22. Bonniaud P, Margetts PJ, Kolb M, et al. Adenoviral gene transfer of connective tissue growth factor in the lung induces transient fibrosis. Am J Respir Crit Care Med 2003;168:770-8.
23. Dabrosin C, Palmer K, Muller WJ, Gauldie J. Estradiol promotes growth and angiogenesis in polyoma middle T transgenic mouse mammary tumor explants. Breast Cancer Res Treat 2003;78:1-6.
24. Schor AM, Pendleton N, Pazouki S, et al. Assessment of vascularity in histological sections: effects of methodology and value as an index of angiogenesis in breast tumours. Histochem J 1998;30:849-56.
25. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-44.
26. Bergman Jungestrom M, Thompson LU, Dabrosin C. Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo. Clin Cancer Res 2007;13:1061-7.
27. Dabrosin C. Microdialysis - an in vivo technique for studies of growth factors in breast cancer. Front Biosci 2005;10:1329-35.
28. Dabrosin C, Chen J, Wang L, Thompson LU. Flaxseed inhibits metastasis and decreases extracellular vascular endothelial growth factor in human breast cancer xenografts. Cancer Lett 2002;185:31-7.
29. Abdollahi A, Hahnfeldt P, Maercker C, et al. Endostatin's antiangiogenic signaling network. Mol Cell 2004;13:649-63.
30. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
31. Abdollahi A, Hlatky L, Huber PE. Endostatin: the logic of antiangiogenic therapy. Drug Resist Updat 2005;8:59-74.
32. Stetler-Stevenson WG, Hewitt R, Corcoran M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol 1996;7:147-54.
33. Pozzi A, LeVine WF, Gardner HA. Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene 2002;21:272-81.
34. 1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci U S A 2000;97:2202-7.
35. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000;19:6642-50.
36. Kopitz C, Gerg M, Bandapalli OR, et al. Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res 2007;67:8615-23.
37. Lipton A, Ali SM, Leitzel K, et al. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer. Cancer 2007;109:1933-9.
38. Miyagi M, Aoyagi K, Kato S, Shirouzu K. The TIMP-1 gene transferred through adenovirus mediation shows a suppressive effect on peritoneal metastases from gastric cancer. Int J Clin Oncol 2007;12:17-24.
39. Moore MJ, Hamm J, Dancey J, et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21:3296-302.